Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 302, Issue 1, Pages 49-57Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.943
Keywords
-
Categories
Funding
- Swedish Medical Research Council
- Swedish Heart and Lung Foundation
- Medical Faculty of Lund University
- Malmo University Hospital
- Albert Pahlsson Research Foundation
- Crafoord foundation
- Ernhold Lundstroms Research Foundation
- Region Skane
- Hulda and Conrad Mossfelt Foundation
- King Gustaf V and Queen Victoria Foundation
- Lennart Hanssons Memorial Fund
- Wallenberg Foundation
- National Institutes of Health (NIH) [K23-HL-080025, R01-HL-086875, R01-HL083197, R01-DK-081572]
- Doris Duke Charitable Foundation Clinical Scientist Development Award
- Burroughs Wellcome Fund Career Award for Medical Scientists
- American Heart Association
Ask authors/readers for more resources
Context Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment. Objective To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors. Design, Setting, and Participants Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmo, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP) and underwent follow-up until 2006 using the Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmo register for first cardiovascular events (myocardial infarction, stroke, coronary death). Main Outcome Measures Incident cardiovascular and coronary events. Results During median follow-up of 12.8 years, there were 418 cardiovascular and 230 coronary events. Models with conventional risk factors had C statistics of 0.758 (95% confidence interval [CI], 0.734 to 0.781) and 0.760 (0.730 to 0.789) for cardiovascular and coronary events, respectively. Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased the C statistic by 0.007 (P = .04) and 0.009 (P = .08), respectively. The proportion of participants reclassified was modest (8% for cardiovascular risk, 5% for coronary risk). Net reclassification improvement was nonsignificant for cardiovascular events (0.0%; 95% CI, -4.3% to 4.3%) and coronary events (4.7%; 95% CI, -0.76% to 10.1%). Greater improvements were observed in analyses restricted to intermediate-risk individuals (cardiovascular events: 7.4%; 95% CI, 0.7% to 14.1%; P = .03; coronary events: 14.6%; 95% CI, 5.0% to 24.2%; P = .003). However, correct reclassification was almost entirely confined to down-classification of individuals without events rather than up-classification of those with events. Conclusions Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events. JAMA. 2009;302(1):49-57
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available